Company Description
OS Therapies Incorporated is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors.
Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
Our pipeline includes two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, or a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides, and (ii) OST-TDC, a next generation tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers™).
The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.
We intend to expand our pipeline beyond Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including breast, esophageal and lung cancers.
With the addition of our OST-Tunable Drug Conjugate (OST-TDC) platform, we will be targeting ovarian, lung and pancreatic cancers.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 10, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Paul A. Romness, MPH |
Contact Details
Address: 15825 Shady Grove Road, Suite 135 Rockville, MD 20850 United States | |
| Phone | (410) 297-7793 |
| Website | ostherapies.com |
Stock Details
| Ticker Symbol | OSTX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001795091 |
| Employer ID | 82-5118368 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul A. Romness, MPH | Founder, President, Chief Executive Officer and Director |
| Robert G. Petit, Ph.D. | Chief Medical Officer and Chief Scientific Officer |
| Alan A. Musso | Chief Financial Officer |
| Colin Goddard, Ph.D. | Chairman of the Board |
| Joacim Borg | Director |
| John Ciccio | Director |
| Theodore F. Search, Pharm.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 7, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 3, 2024 | RW | Filing |
| Jun 3, 2024 | RW | Filing |
| May 30, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 30, 2024 | RW | Filing |
| May 20, 2024 | 10-Q | Quarterly Report |
| May 20, 2024 | SP 15D2 | Filing |
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 15, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |